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Background: Hereditary Breast and Ovarian Cancer Syndrome (HBOCS) and Hereditary Non-Polyposis Colorectal
Cancer Syndrome (HNPCC, Lynch Syndrome) are two tumor predisposition syndromes responsible for the majority
of hereditary breast and colorectal cancers. Carriers of both germline mutations in breast cancer genes BRCA1 or
BRCA2 and in mismatch repair (MMR) genes MLH1, MSH2, MSH6 or PMS2 are very rare.
Case presentation: We identified germline mutations in BRCA1 and in MSH6 in a patient with increased risk for
HBOC diagnosed with endometrial cancer at the age of 46 years.
Conclusions: Although carriers of mutations in both MMR and BRCA genes are rare in Caucasian populations and
anamnestical and histopathological findings may guide clinicians to identify these families, both syndromes can
only be diagnosed through a complete gene analysis of the respective genes.Background
Hereditary Breast and Ovarian Cancer Syndrome
(HBOCS) is an autosomal dominantly inherited disease
caused by mutations in BRCA1 or BRCA2 and charac-
terized by young age of onset, synchronous or metachro-
nous disease, and a family history of first and second
degree relatives with breast and/or ovarian cancer. De-
pending on the affected gene, the estimated lifetime risks
range from 46-85% for breast and 11-53% for ovarian
cancer [1,2].
Lynch syndrome (hereditary non-polyposis colorectal
cancer, HNPCC), is also an autosomal dominant tumor
predisposition caused by germline mutations in DNA
mismatch repair (MMR) genes MLH1, MSH2, MSH6 or
PMS2 with a life-time risk for colorectal cancer (CRC) of
up to 80% and considerably increased risk of developing
a broad spectrum of extracolonic malignancies including,
among others, endometrial cancer (EC), stomach cancer
and ovarian cancer [3,4]. In females, the cumulative risk* Correspondence: karin.kast@uniklinikum-dresden.de
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reproduction in any medium, provided the orfor EC is 17-57% and almost equally high for CRC [5-8].
In MSH6 gene mutation carriers, CRC and ovarian can-
cer risks are lower [9]. However, MSH6 is only affected in
a small fraction of all MMR gene mutation carriers [6,8].
Little is known about the phenotype of families with
double mutations causing both HNPCC and HBOCS.
Therefore, we report on a female index patient in a
family fulfilling the criteria for HBOCS which developed
endometrial cancer at age 46 and was identified as a
double heterozygous germline mutation carrier.
Case presentation
The index patient of the family (individual III:1) was
diagnosed with early stage endometrioid endometrial
cancer at the age of 46 years, thus almost meeting the
original Bethesda Guideline 4 [10]. She was referred to
our Center for Hereditary Breast and Ovarian Cancer
because of the early demise of her sister (III:2) due to
triple negative breast cancer at the age of 33 years. Like-
wise, her mother (II:2) suffered from triple negative breast
cancer at the age of 56. Her maternal aunt (II:5) had
papillary-serous ovarian cancer at the age of 43 and
additionally had been diagnosed with cervical squamous
cell carcinoma at the age of 40. Moreover, the patient. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gastric cancer at the age of 67 years (no histologic or
pathologic report were available). Four further maternal
aunts and uncles and all of their children had not been
reported for malignant diseases. One case of abdominal
cancer of unknown origin (II:13) was reported in the
paternal pedigree (Figure 1). All family members with
breast or ovarian cancer had died. After counseling of
the index patient and obtaining informed consent,
analysis of the breast cancer genes BRCA1 and BRCA2
and testing for HNPCC was performed.
DNA-analysis of BRCA genes 1 and 2 was carried out
by pre-screening of DNA extracted from lymphocytes of
the index patient (III:1) with DHPLC (Denaturing High
Performance Liquid Chromatography) using the WAVEW
System 2100 (Transgenomic Ltd, United Kingdom) as
described elsewhere [11]. Sanger sequencing of suspect
fragments revealed the pathogenic BRCA1 mutation
c.213-12A>G, p.Arg71SerfsX21. This nucleotide change
is predicted to form a cryptic splice site resulting in the
addition of 11 nucleotides to the BRCA1 transcript and
a truncated protein [12]. Immunohistochemical staining
(IHC) of MMR proteins MLH1, MSH2, MSH6 and PMS2
was carried out on formalin-fixed, paraffin-embedded
tumor sections of the endometrial cancer of individual
III:1 as described elsewhere [13]. Loss of expression of
MSH6 was identified. Consequently, sequencing of the
MSH6 gene was performed using primers and conditions
described elsewhere [14], which revealed the pathogenic
mutation c.515_516insT, p.Ile172fsX10.
The index patient (III:1) was thus identified as a
carrier of pathogenic germline mutations in both BRCA1
and MSH6. At the time of counseling she was 51 years





















































Figure 1 Pedigree. The black arrow indicates the index patient and the b
Documentation was not available for the “gastric cancer” reported in I:1. Ab
neg. ‐ negative.stage pT1a pNx G3 (FIGO IA) and was treated with hys-
terectomy, bilateral adnexectomy and resection of the
upper proximal part of the vagina. Although facing a
lifelong estimated risk for breast cancer of up to 80% [2]
she decided against preventive surgery. In addition to
breast cancer surveillance, screening exams for HNPCC-
associated tumors according to the German HNPCC
Consortium [15] have been regularly performed in the
last three years without pathological findings.
Her sister (III:3) and her nieces (IV:5 and IV:6) under-
went predictive testing for the BRCA1 mutation of which
IV:5 was identified to be a carrier. The sister (III:3) of the
index patient and one niece (IV:5) were tested for
the familial MSH6 mutation and none of them carries
the mutation. At the time of writing this article, no
further predictive testings have been carried out in
other family members.
Conclusions
To date, only two families with co-occurrence of a
MMR and BRCA1/BRCA2 mutation have been reported
[16,17]. Thiffault et al. described two protein truncating
mutations in MSH2 and BRCA2 identified in one female
individual with breast cancer at the age of 32 and colon
polyps at the age of 40. The patient’s father (who had
died at the age of 36 years) was an obligate carrier of
both mutations and had CRC at 32 years. The female
patient described by Borg et al. carried two MLH1 mis-
sense mutations (one of which segregating with familial,
Lynch syndrome associated tumors) plus a BRCA1
mutation, being diagnosed with breast cancer at the age
of 35 years. The reported tumors in these patients and
the hereby reported case do not exceed the spectrum of








cervical cancer AO 40











































lack dot the unaffected female carrier of the familial BRCA1 mutation.
breviations: AO- age of onset, mut. ‐ mutation, pos. ‐ positive,
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germline mutation in the respective MMR or BRCA
genes alone.
In our family, the only Lynch syndrome associated
malignancy was the EC in the index patient. Although
three other cancers in both family branches (I:1, I:2,
II:13) have been described, no proof of the tumor origin
and/or pathology findings were available. It cannot be
determined from the pedigree whether the MSH6 muta-
tion originates from the maternal or paternal side. Since
it is unlikely that the MSH6 mutation represents a de
novo mutation, the low frequency of Lynch Syndrome
associated cancers in both branches of the family may be
due to reduced penetrance of MSH6 mutations [8,9,18].
So far, only two members of the family consented for
predictive testing for the MSH6 mutation, none of which
carried the mutation.
No consensus exists regarding the association of breast
cancer with Lynch Syndrome. Although MSI has been
described in most breast cancers of HNPCC kindreds,
the risk for breast cancer is not elevated in most families
[5,19-23]. However, a recent prospective study revealed
an almost four-fold increase of breast cancer incidence
in carriers of a mutation in the HNPCC-genes [24]. More-
over, Scott et al. reported on a significant overrepresenta-
tion of breast cancers in MLH1 mutation carriers [25].
Triple negativity has been shown to be strongly asso-
ciated with mutation carrier status of BRCA1 [26]. Thus,
two triple negative breast cancers and the presence of an
ovarian cancer strongly suggested a BRCA1-associated
disease in this family (Figure 1). Furthermore, a slightly
increased risk for uterine and cervical cancer as well as
colorectal cancer has also been reported for BRCA1
mutation carriers [27]. The uterine cancer of III:1 could
therefore be misinterpreted as caused by the BRCA1
germline mutation. Nevertheless, HBOCS-associated
uterine cancers tend to be of serous papillary type,
whereas HNPCC-associated uterine cancers typically are
of endometrial type, as in our case [28]. Proven by loss
of expression of MSH6 the EC in patient III:1 is due to
the germline MSH6 mutation. Additionally, the above
mentioned higher rate of cervical cancers may be due to
the interaction of the HPV oncogenes E6 and E7 with
BRCA1, which has been shown to render the cervix
more susceptible to cancer [29].
The incidence of ovarian cancer in HBOCS is higher than
in Lynch Syndrome. Additionally, BRCA1-associated
ovarian cancers often show high grade serous histology,
whereas HNPCC-associated ovarian cancers often display
endometrioid histology [23,30]. Therefore, the ovarian can-
cer of individual II:5 was most probably BRCA1-associated.
It can be assumed that revised Bethesda Guidelines
recommendations for the identification of colorectal
tumors that should be tested for MSI, sometimes fail toidentify individuals with HNPCC. To avoid non-
identification of HNPCC-patients it might be reasonable
to screen both, colorectal and endometrial cancer tumor
specimens for MMR-defect. Interestingly, this topic has
been discussed at least for colorectal cancer at the
HNPCC workshop conducted by the NCI in Bethesda,
MD in 2002. Although participants voted to keep less
than 60 years of age in the guideline 3 there was no
consensus on whether to include the age criteria [4].
Data from the Robert Koch Institute German Cancer
Registry (http://www.rki.de) indicate that the incidence
of HNPCC associated cancers such as colorectal, small
bowel, urinary tract, and endometrial cancer is about 6%
in the German population. Assuming that 5% of these
tumors are caused by MMR gene mutations with a
penetrance of 80%, the allele frequency in the German
population is 0.38% [31]. Incidence of breast cancer is
9.53% in the German female population. On the as-
sumption that 5% of these tumors are caused by BRCA1
or BRCA2 mutations with a penetrance of 85% and that
the allele frequency is similar in the male population, the
allele frequency in the whole German population is 0.6%
[32,33]. Therefore, the probability to be a carrier of both
mutations in breast cancer genes and MMR genes is
1/167 × 1/260 × 1/4 = 1/174.800, which sums up to 470
carriers of both alleles in the German population. Since
allele frequencies are similar in Western populations the
frequency of carriers of both alleles may be up to 5.7 per
one million individuals.
Although carriers of mutations in both MMR and BRCA
genes are rare in Caucasian populations, anamnestical and
histopathological findings may guide clinicians to identify
these families. Firstly, meeting both Bethesda Guidelines
and HBOCS Criteria may raise suspicion of both
syndromes in one family. Secondly, this may be substan-
tiated by specific histological findings in available
tumors, such as triple negative breast cancers (BRCA1-
associated), high grade papillary serous ovarian cancer
(BRCA1- and 2-associated), endometrioid cancer of
the uterus (MMR-gene-associated) and microsatellite
instability (MMR-gene-associated). Finally, both syn-
dromes can only be diagnosed through a complete
gene analysis of the respective genes.
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